Financial Snapshot

Revenue
$10.45M
TTM
Gross Margin
Net Earnings
-$269.4M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
105.69%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$5.892M
Q3 2024
Cash
Q3 2024
P/E
-0.5960
Dec 02, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $9.993M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $9.993M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $20.62M $27.32M $43.05M $32.68M $13.23M $2.050M $580.0K
YoY Change -24.5% -36.55% 31.73% 147.01% 545.37% 253.45%
% of Gross Profit
Research & Development $53.91M $55.63M $62.57M $61.79M $32.35M $11.47M $3.700M
YoY Change -3.11% -11.09% 1.27% 91.0% 182.04% 210.0%
% of Gross Profit
Depreciation & Amortization $2.000K
YoY Change
% of Gross Profit
Operating Expenses $74.53M $82.95M $105.6M $94.47M $45.58M $13.52M $4.290M
YoY Change -10.15% -21.46% 11.81% 107.25% 237.13% 215.15%
Operating Profit -$64.54M -$82.95M -$105.6M -$94.47M
YoY Change -22.2% -21.46% 11.81%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $1.372M $685.0K $555.0K $559.0K $90.00K -$2.780M $0.00
YoY Change 100.29% 23.42% -0.72% 521.11% -103.24%
% of Operating Profit
Other Income/Expense, Net -$55.23M $442.0K $34.00K $505.0K -$20.00K
YoY Change -12595.02% 1200.0% -93.27% -2625.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$119.8M -$82.51M -$105.6M -$93.96M -$45.51M -$16.52M -$4.280M
YoY Change 45.15% -21.86% 12.37% 106.46% 175.48% 285.98%
Income Tax
% Of Pretax Income
Net Earnings -$119.8M -$82.51M -$105.6M -$93.96M -$45.51M -$16.52M -$4.280M
YoY Change 45.15% -21.86% 12.37% 106.46% 175.48% 285.98%
Net Earnings / Revenue -1198.47%
Basic Earnings Per Share -$1.42 -$2.18 -$4.12 -$4.28
Diluted Earnings Per Share -$1.42 -$2.18 -$4.12 -$4.28 -$3.547M -$968.9K -$251.0K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $50.15M $30.58M $80.82M $96.80M $38.90M $18.70M $3.300M
YoY Change 64.0% -62.16% -16.51% 148.84% 108.02% 466.67%
Cash & Equivalents $49.90M $16.66M $53.89M $57.50M $18.90M $18.70M $3.300M
Short-Term Investments $254.0K $13.92M $26.94M $39.40M $20.00M
Other Short-Term Assets $4.234M $6.728M $7.571M $5.800M $7.300M $1.500M $0.00
YoY Change -37.07% -11.13% 30.53% -20.55% 386.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $54.39M $37.31M $88.39M $102.6M $46.20M $20.20M $3.300M
YoY Change 45.78% -57.79% -13.85% 122.08% 128.71% 512.12%
Property, Plant & Equipment $447.0K $857.0K $1.298M $1.700M $2.000M
YoY Change -47.84% -33.98% -23.65% -15.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $198.0K $200.0K $200.0K $200.0K
YoY Change -100.0% -1.0% 0.0% 0.0%
Total Long-Term Assets $447.0K $1.055M $1.498M $1.900M $2.200M $0.00 $0.00
YoY Change -57.63% -29.57% -21.16% -13.64%
Total Assets $54.83M $38.36M $89.89M $104.5M $48.40M $20.20M $3.300M
YoY Change
Accounts Payable $1.742M $4.534M $9.461M $600.0K $8.800M $3.000M $700.0K
YoY Change -61.58% -52.08% 1476.83% -93.18% 193.33% 328.57%
Accrued Expenses $15.72M $15.23M $16.01M $20.00M $5.000M $1.400M $300.0K
YoY Change 3.16% -4.88% -19.93% 300.0% 257.14% 366.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $71.18M $33.42M $26.46M $21.20M $14.10M $4.400M $1.000M
YoY Change 112.97% 26.31% 24.82% 50.35% 220.45% 340.0%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $797.0K $878.0K $891.0K $1.300M $1.700M
YoY Change -9.23% -1.46% -31.46% -23.53%
Total Long-Term Liabilities $797.0K $878.0K $891.0K $1.300M $1.700M $0.00 $0.00
YoY Change -9.23% -1.46% -31.46% -23.53%
Total Liabilities $71.98M $34.30M $27.35M $22.60M $15.80M $4.400M $1.000M
YoY Change 109.84% 25.4% 21.03% 43.04% 259.09% 340.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 84.24M 37.83M 25.60M 21.97M
Diluted Shares Outstanding 84.24M 37.83M 25.60M 21.97M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $160.57 Million

About Applied Therapeutics, Inc.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2019-05-09. The company is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The firm is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. The company has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

Industry: Pharmaceutical Preparations Peers: DYADIC INTERNATIONAL INC Quince Therapeutics, Inc. EXAGEN INC. Galera Therapeutics, Inc. Immunome Inc. Lantern Pharma Inc. Minerva Neurosciences, Inc. MUSTANG BIO, INC. Synaptogenix, Inc.